A Study to Compare the Efficacy and Safety of Pegvisomant to that of Sandostatin LAR in Patients with Acromegaly

The pupose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Condition:- Acromegaly Study Type: InterventionalStudy Design: Treatment Eligibility Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Criteria Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria:Diagnosis of acromegaly IGF-I levels >=1.3xULN (upper limit of normal) at screening No history of radiotherapy or prior treatment with other drugs for acromegaly Minimum of two months must have elapsed post surgery prior to screening Exclusion Criteria:Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations AST/ALT >= 3xULN (upper limit of normal) Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI Visual field defects (except post surgical stable residual defects) Unable to self administer drug Contact Details:Australia, New South WalesResearch Center, Darlinghurst, New South Wales, 2010, Australia; Recruiting Australia, VictoriaResearch Center, Fitzroy, Victoria, 3065, Australia; Recruiting